TopPodcast.com
Menu
  • Home
  • Top Charts
  • Top Networks
  • Top Apps
  • Top Independents
  • Top Podfluencers
  • Top Picks
    • Top Business Podcasts
    • Top True Crime Podcasts
    • Top Finance Podcasts
    • Top Comedy Podcasts
    • Top Music Podcasts
    • Top Womens Podcasts
    • Top Kids Podcasts
    • Top Sports Podcasts
    • Top News Podcasts
    • Top Tech Podcasts
    • Top Crypto Podcasts
    • Top Entrepreneurial Podcasts
    • Top Fantasy Sports Podcasts
    • Top Political Podcasts
    • Top Science Podcasts
    • Top Self Help Podcasts
    • Top Sports Betting Podcasts
    • Top Stocks Podcasts
  • Podcast News
  • About Us
  • Podcast Advertising
  • Contact
Not in our directory?
Add Show Here
Podcast Equipment
Center

toppodcastlogoOur TOPPODCAST Picks

  • Comedy
  • Crypto
  • Sports
  • News
  • Politics
  • True Crime
  • Business
  • Finance

Follow Us

toppodcastlogoStay Connected

    View Top 200 Chart
    Back to Rankings Page
    Life Sciences

    BiotechTV – News

    This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

    Advertise

    Copyright: © BiotechTV

    • Apple Podcasts
    • Google Play
    • Spotify

    Latest Episodes:
    Oxford's OrganOx became one of the UK's biggest news stories when it was announced it would be acquired by Japan's Terumo for approximately $1.5 billion - here's the revolutionary technology behind it Oct 10, 2025
    Show notes

    CEO Craig Marshall describes how the company's "metra" device pumps blood through donor organs (currently livers) in order to extend the amount of time they can be transplanted safely.


    Oxford, UK based OMass Therapeutics, experts in the use of mass spectrometry in drug development, recently landed a $20M up front licensing deal with Roche on one of its preclinical candidates for IBF Oct 09, 2025
    Show notes

    CEO Ros Deegan discusses the deal and the path to getting there, and she highlights some of OMass' other programs the company is driving forward alone, including an MC2 antagonist. Plus, the company's unique expertise in the use of mass spec.


    NYSE Market Strategist Eric Criscuolo discusses biotech's newfound momentum and whether it might attract generalists to take a look at the sector Oct 09, 2025
    Show notes

    He discusses the rally biotech has had of late, and that was boosted by Pfizer's deal with the White House. Plus, how interest rates, employment, and other factors are affecting the broader economy, and might impact biotech.


    Immuneering's CEO walks us through the company's MEK data in pancreatic cancer, and explains the science behind 'deep cyclic inhibition' Oct 09, 2025
    Show notes

    Ben Zeskind describes the company's 9 month follow-up for atebimetinib + mGnP, which showed 86% overall survival and 53% progression free survival.


    R.W. Baird Managing Director & Senior Biotech Analyst Brian Skorney discusses numerous battleground companies in biotech Oct 08, 2025
    Show notes

    He shares his thoughts on Soleno, Sarepta, Lexeo, Enanta, Crinetics, Vertex, Xenon, and more.


    Biotech veteran David Hung talks about the launch of IBTROZI in ROS1 positive non-small cell lung cancer, and what's next for Nuvation Bio Oct 08, 2025
    Show notes

    He discusses the clinical profile of IBTROZI, how the launch is going, and describes other work the company is doing in precision medicine. Plus, his take on the biotech environment currently.


    Complement Therapeutics received IND clearance from U.S. FDA today to start a trial of its AAV gene therapy for geographic atrophy that delivers a truncated version of Complement Receptor 1 to the eye Oct 08, 2025
    Show notes

    CEO Rafiq Hasan describes to BiotechTV's Amy Brown during an interivew in London how this program works, and he compares and contrasts it to more traditional therapies that are on the market currently. Plus, and overview of Complement's other programs and operations.


    Align Summit: Cambridge based Quiver Bioscience is developing ASOs for CNS conditions, including having programs in the red hot Nav1.7/1.8 pain space Oct 07, 2025
    Show notes

    Co-Founder & CEO Graham Dempsey describes the different between Nav1.7 and 1.8, and why he thinks having an ASO approach will succeed in 1.7 where small molecules have not. Plus, an epilepsy program, and what it is like being an earlier stage company today.


    Align Summit: Toronto based HDAX Therapeutics believes there are many indications to tackle with its dual binding approach to HDAC6 Oct 07, 2025
    Show notes

    Co-Founder & CEO Nabanita Nawar describes the need for tackle HDAC6 with better chemistry. Plus, what it is like being a biotech startup in Canada today.


    Align Summit: Allston based KiraGen Bio is aiming to program CAR-T cells to tune out the suppressive nature of the tumor micro environment. The first program will be for GBM. Oct 07, 2025
    Show notes

    Co-Founder and CEO Aaron Edwards describes the rational behind this approach, as opposed charging the cells with cytokines or removing their brakes. He also explains why KiraGen is looking abroad to do its first clinical trials.


    Previous 1 23 24 25 26 27 49 Next

    Related Podcasts

    Science Friday

    1

    Science Friday Astronomy
    The Naked Scientists Podcast

    2

    The Naked Scientists Podcast Life Sciences
    Stuff To Blow Your Mind

    3

    Stuff To Blow Your Mind Life Sciences
    Stuff To Blow Your Mind

    4

    Stuff To Blow Your Mind Life Sciences
    Brain Science with Ginger Campbell, MD: Neuroscience for Everyone

    5

    Brain Science with Ginger Campbell, MD: Neuroscience for Everyone Health & Fitness
    All In The Mind

    6

    All In The Mind Government & Organizations
    footer-logo

    Contact Us

    Toll Free: 844-670-7747

    Links

    • Home
    • Top Charts
    • Networks
    • Apps
    • Independents Podcasts
    • Podcast Advertising
    • Podcast News
    • Contact Us
    • About Us
    • Analytics & Insights

    Stay Connected

      Privacy, Terms of Use & Our Code of Ethics Protecting Content Creators Copyrights